Providers
Built for care teams. Designed to scale.
Glidepath is purpose-built to help your care team manage and scale your cell and gene therapy program with full transparency, from referral through infusion.
The platform is available to providers at no cost.
Proven at the point of care
Glidepath’s technology originated at a leading cancer center that set out to solve this exact problem for its own advanced therapy program, not as a hypothetical, but as a day-to-day operational need.
Speed to infusion
Coordinate apheresis, manufacturing, and shipment slots with real-time cold chain tracking and full chain-of-custody documentation, plus product-specific onboarding, so therapy reaches the patient faster, with nothing lost or delayed, saving up to 20 hours of unreimbursable time per case.1
More patients per coordinator
AI-driven workflows automatically assign and prioritize tasks on a single patient dashboard, tracking milestones from referral through infusion and streamlining caregiver coordination, so coordinators manage more patients without missed handoffs.
Fewer compliance misses
AI-reviewed compliance monitoring flags gaps before they become audit findings, with a full FACT-ready audit trail, real-time risk alerts, and certification tracking that keeps sites continuously audit-ready.
1. Based on Glidepath primary market research and internal analysis.
One platform. Every advanced therapy. End to end.
Glidepath is an AI-driven platform fully integrated with critical hospital systems, including the EHR, to give care teams a single end-to-end view across every advanced therapy program, from referral through infusion and beyond.
See every active patient’s journey stage across all cell and gene therapy products the hospital offers, and support the care team on administrative next steps.
Aggregated, hospital-level analytics on CGT program performance and internal capacity utilization.
Evaluate your metrics against peer institutions through anonymous benchmarking.
